Page 25 - Vitamin D and Cancer
P. 25

12                                                         H.S. Cross

            Enhanced synthesis and accumulation of 1,25-(OH) D  in the colon mucosa would
                                                     2  3
            be responsible for up-regulation of transcriptional activity of CYP24A1 [34] and
            also for autocrine/paracrine inhibition of tumor cell growth. We suggest that this
            enhanced expression of CYP27B1 could be due, at least in part, to epigenetic regu-
            lation, i.e., demethylation, while raised CYP24A1 expression probably results from
            the  normal  regulatory  loop  following  accumulation  of  1,25-(OH) D   in  colonic
                                                                  2  3
            mucosa. However, in highly malignant tumors, an efficient antimitogenic effect by
            1,25-(OH) D  is unlikely, because expression of the catabolic vitamin D hydroxy-
                    2  3
            lase  by  far  exceeds  that  of  CYP27B1.  Our  hypothesis,  therefore,  is  that  during
            cancer  progression  CYP27B1  would  be  inactivated  by  epigenetic  mechanisms,
            whereas that of CYP24A1 would be activated. To test this, we studied expression
            of vitamin D hydroxylases in 105 colon tumor patients entering a Viennese hospital
            for  tumor  resection.  Uncoupling  of  CYP24A1  expression  from  regulation  by
            colonic 1,25-(OH) D  would lead to vitamin D hydroxylase expression in opposite
                          2  3
            directions during progression to a highly malignant state. This is actually the case:
            Transition from low- to high-grade cancers is associated with a further highly signifi-
            cant rise in CYP24A1 mRNA expression and a simultaneous decline of CYP27B1
            activity  (Fig.  1.2).  Analysis  of  a  selected  (small)  number  of  tumor  biopsies



                                    CYP24A1  and CYP27B1  mRNA
                         22
                                                         ***
                         20      CYP24A1
                         18      CYP27B1
                       NM]  16              ***
                         14
                       [fold  12
                       Gene expression  10 8 6    *







                          2 4
                          0
                         –2
                          N =  10   10      59   59      4 6  46
                                 NM          G1+G2        G3+G4
            Fig. 1.2  CYP24A1 and CYP27B1 mRNA expression in 105 colon cancer patients. n = 59 patients
            with G1/G2 (highly to moderately differentiated) tumors; n = 46 patients with G3/G4 (low and
            undifferentiated) tumors. Cancer patient data were compared with those derived from non-cancer
            (NM) patients (tissue from stoma reoperations after diverticulitis surgery) n = 10. Densitometric
            data of tumor patients were expressed in fold increase compared to NM. Significant differences
            are expressed as: *p £ 0.05; ***p £ 0.001
   20   21   22   23   24   25   26   27   28   29   30